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The highly interdependent relationship between the heart and kidneys was described as early as in 1836 by Sir Richard Bright, who identified cardiac structural abnormalities in a series of patients with advanced chronic kidney 
disease.1 Around the same time in 1835, French chemists isolated phlorizin, a 
natural, nonselective inhibitor of SGLT1 (sodium glucose co-transporter 1) and 
SGLT2, as part of early attempts to create an animal model for diabetes. Since 
then, despite major developments in cardiorenal and metabolic medicine, there 
has been a relative chasm between availability of new approaches to optimize 
cardiovascular and kidney outcomes and their implementation in clinical practice. 
With the advent of the sodium glucose cotransporter 2 inhibitors (SGLT2is) and 
the glucagon-like receptor-1 agonists and other new cardiorenal protective thera-
pies, the spheres of cardio-nephrology and metabolic medicine have converged in 
unprecedented ways with the potential for population-level improvements in mul-
tidomain health. However, despite high-quality evidence for cardiovascular and 
kidney protection afforded by these agents, these therapies seem mismatched 
with population risk such that they are not reaching the highest risk patients 
with established cardiovascular and/or kidney disease.2,3 For instance, in one 
study, younger, healthier, and non-Black patients were most likely to start SGLT2i, 
although patients with cardiovascular or kidney disease were less likely to use 
SGLT2i from 2013 to 2018.3 This perspective piece explores potential explanations 
for the underutilization and appropriate deployment of risk-reduction strategies 
in patients with  type 2 diabetes mellitus, kidney disease, and/or cardiovascular 
disease, and offers the concept of a multidisciplinary cardio-renal-metabolic care 
model that may help overcome some of these barriers.
DISPARITIES IN SPECIALTY RESOURCES AND SILO CARE
In the United States, there is wide variation in the volume of the specialty work-
force across cardiology, nephrology, and endocrinology. Specialty care access is 
substantially limited in certain geographic regions.4 In addition, reduced retention 
rates of internal medicine trainees as primary care physicians further compounds 
their existing shortage as a central part of the care team for patients with complex 
chronic diseases. As such, it is conceivable that limited access to necessary care may 
limit introduction of effective risk-reducing interventions. Specialists may genu-
inely be limited in their office-based resources with respect to monitoring complex 
patients closely after initiation of these agents and may choose to prioritize work-
flow aligned with their existing practice patterns, rather than take on new chal-
lenges. Beyond resource distribution and support issues, siloed care may contribute 
to increase therapeutic inertia. As an example, there is a reluctance on the part 
of cardiologists and nephrologists to initiate SGLT2i or glucagon-like  receptor-1 
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agonists, despite high-quality supporting data for their 
cardiorenal benefits, likely driven by several factors such 
as the need to add diabetes management to existing 
subspecialist responsibilities, adjust antidiabetic thera-
pies prescribed by other physicians and handle prior 
authorizations, inadequate insurance coverage and 
excess out-of-pocket cost issues. Last, communication 
between specialists and primary care physicians tends 
to be fragmented, and compensation models that pri-
oritize high patient volumes and procedures may limit 
opportunities to optimize medical management.
BLIND SPOTS IN THE KNOWLEDGE 
BASE
Superimposed on the workforce-related disparities, 
there exist knowledge gaps and different perspec-
tives that may impede optimal delivery of therapies 
even when a patient has access to a full spectrum 
of appropriate specialists. Examples of these include 
the underutilization of renin angiotensin inhibitors, 
the SGLT2i or intensive blood pressure control strate-
gies because of the inaccurate perception of elevated 
risks of acute kidney injury.5,6 These differences in 
clinical approach stem from reliance on standardized 
definitions of acute kidney injury, which may not be 
applicable in these scenarios where hemodynamically 
mediated fluctuations in glomerular filtration markers 
commonly occur, which do not represent true intrin-
sic kidney injury. Given these interventions affect mul-
tiple disease states and multiorgan health, there is 
a need for broad education across specialties about 
the nuances and limitations of commonly used defini-
tions and terms in the cardiorenal metabolic space, to 
ensure that a common language is in place that will 
facilitate a multidisciplinary care model.
ECONOMIC DISINCENTIVE FOR 
INTEGRATED CARE
While seamless integration of care across specialties 
may be beneficial to patients, there may be potential 
barriers with respect to current specialty workflow 
and reimbursement models. Outside of a few health 
systems with value-based models that incentivize high-
quality care, most health systems reward quantity over 
quality. Thus, without creating new reimbursement 
models for physicians engaging in cross-disciplinary col-
laborations, it is impossible to sustain these models of 
care over time. Currently, one of the barriers to an inte-
grated model of care is the lack of insurance reimburse-
ment when multiple clinicians see the same patient in a 
select practice on a given day. Having a single specialist 
invested in multisystem health evaluate the patient in 
an initial encounter followed by staggered subsequent 
specialty engagement may help offset this problem and 
guard against large gaps in care.
CARDIO-RENAL-METABOLIC CARE 
MODELS
There is an unmet need to create sustainable and 
seamless multidisciplinary care models for cardio-renal-
metabolic disease especially as effective therapies have 
emerged that reduce mortality and cardiorenal compli-
cations.7 To this end, we offer several suggestions that 
may help individual physicians, practices, hospitals, and 
specialty organizations consider implementing a cardio-
renal-metabolic care model (Figure).
Training and Education
1. Facilitate educational opportunities for cardiol-
ogy, nephrology, and endocrinology trainees in 
teaching hospitals. Examples would be the cre-
ation of cardio-renal-metabolic teaching confer-
ences and journal clubs for internal medicine 
residents and subspecialty fellows. Program lead-
ership for fellowships in these specialties should 
consider providing areas of concentration in car-
diorenal-metabolic medicine during elective rota-
tions across specialties, to support early career 
Figure. Components of a successful cardio-renal-metabolic care model 
at an institutional level.
A successful multidisciplinary model would include physician or advanced 
practice provider, dietician, clinical pharmacist, care navigator, and administrative 
representative from all 3 specialties sharing the care of patients at high risk /with 
established cardio-renal-metabolic disease. Such a program would be based on 
mutually common decision-making algorithms across all 3 specialties, shared 
documentation platforms, frequent interface of the care team members (virtually 
or in-person), and periodic review of clinical outcomes, adverse events, patient 
experience, and program financial viability. Such a model would also incorporate 
patient and caregiver representation to align interventions with patient-centered 
values and therapeutic goals. DKD indicates diabetic kidney disease.
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physicians with a sound knowledge base in this 
interface area. This practice is already in place at 
the corresponding author’s institution with estab-
lished clinical and research pathways for trainees 
in this multidisciplinary area. Incorporation of 
multidisciplinary content in the planning of spe-
cialty conferences at a regional and national level 
will also increase education in this overlap space.
2. Specialty societies may consider providing ave-
nues for certification in this area, with the oppor-
tunity for a cardio-renal-metabolic subspecialty, 
described elsewhere,8–10 which may be integrated 
into existing fellowship training time.
Clinical Restructuring and Quality 
Improvement
1. Create a workflow model that can function seam-
lessly and ensure close communication between 
clinicians, using shared decision algorithms appli-
cable to all specialties, frequent group meetings 
to discuss care outcomes and shared platform for 
medical documentation, where feasible. This may 
not necessarily require shared physical common 
workspace and may be feasibly implemented vir-
tually, as is necessary in many health systems in the 
wake of coronavirus disease 2019 (COVID-19).
2. Advocate for shared costs across specialties 
to fund advanced care providers to maintain 
communication and facilitate patient interac-
tions between specialists and the primary care 
physicians.
3. Encourage the use of a care navigator, dieti-
cian, and clinical pharmacist to help the patient 
navigate each aspect of this multidisciplinary 
care team.
4. Maximize the use of telemedicine visits where 
appropriate to ensure timely access to specialists. 
The swift utilization and uptake of telemedicine in 
the context of COVID-19 provides a scaffold for 
future use in a nonpandemic scenario in areas of 
great need such as cardio-renal-metabolic medi-
cine to reduce disparities in patient access to spe-
cialty care.
Patient, Caregiver, and Community 
Engagement
1. Invite patients and their caregivers to be repre-
sented during reviews of performance of cardio-
renal-metabolic clinics, to incorporate their voice 
into actionable items.
2. Engage with stakeholder organizations at a 
regional and national level in each of these spe-
cialties to advocate for legislative changes in 
financial reimbursement for value-based care 
provided by these multidisciplinary care models to 
promote sustainability. This will help sustain the 
long-term financial viability of these models.
3. Harmonize clinical practice guidelines across spe-
cialties to ensure effective and consistent mes-
saging, to facilitate smooth delivery of common 
goals for clinicians and patients.
4. Promote access to SGLT2is, glucagon-like  receptor-1 
agonists, and other emerging new therapies for 
cardio-renal-metabolic conditions through partici-
pation of payers, pharmacy benefit managers, and 
pharmaceutical companies in strategies for efficient 
uptake of guideline-based treatments.
CONCLUSIONS
There is a pressing need to create a common workflow 
model in cardio-renal-metabolic medicine to address 
the complex needs of this vulnerable patient popula-
tion. With the available state-of-the-art interventions 
that may reduce cardiovascular and kidney risks in these 
patients, it is imperative to align physician expertise and 
workflow with disease overlap states rather than the 
current silos of specialization. These models require 
initiatives across local, regional, and national organi-
zations to implement the necessary changes to ensure 
long-term viability of these multidisciplinary models 
of care. These efforts will support rapid translation of 
scientific discovery over the last decade to improved 
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